CA
IDXX icon

Capitolis Advisors’s Idexx Laboratories IDXX Stock Holding History

Capitolis Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,492
Closed -$8.22M – 308
2021
Q4 		$8.22M Buy
12,492
+7,275
+139% +$4.57M 0.05% 257
2021
Q3 		$3.33M Buy
5,217
+3,879
+290% +$2.61M 0.03% 262
2021
Q2 		$845K Sell
1,338
-781
-37% -$431K 0.01% 308
2021
Q1 		$1.04M Sell
2,119
-2,837
-57% -$1.42M 0.02% 304
2020
Q4 		$2.48M Buy
+4,956
New +$2.22M 0.04% 289

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Capitolis Advisors's IDXX Position: Q1 2022 in Review

Capitolis Advisors sold out of Idexx Laboratories (IDXX) in Q1 2022, closing a stake of 12,492 shares — an estimated $8.22M sold.

Capitolis Advisors first reported a position in IDXX in Q4 2020 and held it in 5 quarters. The position peaked at $8.22M in Q4 2021. 1,032 funds tracked by Wall St. Rank hold IDXX as of Q1 2022.

  • Capitolis Advisors reported no remaining Idexx Laboratories position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 12,492 Idexx Laboratories shares in Q1 2022, an estimated $8.22M.
  • Capitolis Advisors first reported a position in Idexx Laboratories in Q4 2020 and held it in 5 quarters.
  • Capitolis Advisors's Idexx Laboratories position peaked at $8.22M in Q4 2021.
  • 1,032 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.